Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05586152 · ClinicalTrials.gov registry record · Phase 1
Study of INV-102 Ophthalmic Solution in Adults With Moderate Symptomatic Dry Eye Disease
A Phase 1 study of Dry Eye Disease, sponsored by Invirsa.
- Completed
- Registry status
- Phase 1
- Development phase
- 84
- Enrollment target
- 1
- Study location
NCT05586152 is a Phase 1 study of Dry Eye Disease that has completed, run by Invirsa. The registered enrollment target is 84 participants, below the 252-participant average among 33 other Dry Eye Disease trials with a reported enrollment target (67% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05586152, a Phase 1 study of Dry Eye Disease, has completed, sponsored by Invirsa.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 84 participants
- Enrollment target
- 1
- Study location
Study Summary
Phase 1/2, first-in-human, 2-part study to assess topically administered eyedrops of INV-102 during 2-week repeat dosing in subjects with moderate symptomatic dry eye disease. Part 1 will be a Dose Escalation phase across 4 cohorts of subjects to assess safety and tolerability of INV-102, and Part 2 will be an Optional Dose Expansion phase in a fifth cohort of subjects, pending the outcome of Part 1, to assess efficacy of INV-102 in the treatment of moderate symptomatic dry eye disease.
Conditions Studied
Interventions
- DRUG Vehicle
- DRUG INV-102
Study Locations (1)
New York
- iuvo BioScience - Rush
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 84 participants |
| Start Date | 2022-08-30 |
| Est. Completion | 2023-05-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05586152
The ClinicalTrials.gov registry entry for NCT05586152 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 84 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 252-participant average among 33 other Dry Eye Disease trials with a reported enrollment target (67% lower). The listed sponsor is Invirsa, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Dry Eye Disease appearing as the primary indexed condition, and to 2 interventions - of which Vehicle is the first listed.
NCT05586152 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT05586152 about?
NCT05586152 is a clinical study titled "Study of INV-102 Ophthalmic Solution in Adults With Moderate Symptomatic Dry Eye Disease". Phase 1/2, first-in-human, 2-part study to assess topically administered eyedrops of INV-102 during 2-week repeat dosing in subjects with moderate symptomatic dry eye disease. Part 1 will be a Dose Escalation phase across 4 cohorts of subjects to assess safety and tolerability of INV-102, and Part 2...
What is the current status of trial NCT05586152?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 84 participants. The study started on 2022-08-30. Estimated completion is 2023-05-02.
What conditions does trial NCT05586152 study?
This clinical trial studies the following conditions: Dry Eye Disease.
What interventions are being tested in trial NCT05586152?
The interventions under investigation include: Vehicle (DRUG), INV-102 (DRUG).
Who is sponsoring clinical trial NCT05586152?
This trial is sponsored by Invirsa, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05586152 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Dry Eye Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Safety, PK and Efficacy Study of SJP-0132 in Subjects With Dry Eye Disease
COMPLETED · Phase 1
-
Study Evaluating Techniques for Measuring Tear Production
COMPLETED · Phase 1
-
Study to Evaluate the Safety, Tolerability, and Efficacy of OTX-CSI in Subjects With Dry Eye Disease.
COMPLETED · Phase 1
-
A Clinical Study to Evaluate the Effect and Side Effect of a New Artificial Tear Formulation (ABBV-444) Compared to Refresh Optive Unit Dose in Adult Participants With Dry Eye Disease
RECRUITING · Phase 3
-
A Study to Explore Signs, Symptoms, and Biomarkers in Dry Eye Disease Participants Following Anti-inflammatory Treatment
RECRUITING · Phase 4
-
Evaluating the Safety, Tolerability, and Efficacy of GRF312 5% in Participants With Dry Eye Disease (DED).
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.